Tyvaso DPI: Drug-device characteristics and patient clinical considerations

By sjmartinez • November 16, 2023

McEvoy C, Argula R, Sahay S, Shapiro S, Eagan C, Hickey AJ, Smutney C, Dillon C, Winkler T, Davis B, Broderick M, Burger C. Tyvaso DPI: Drug-device characteristics and patient clinical considerations. Pulm Pharmacol Ther. 2023 Nov 13:102266. doi: 10.1016/j.pupt.2023.102266. Epub ahead of print. PMID: 37967762.

Tags: Cardiology/Epi, Inhaled, prostacyclin, Publications, pulmonary arterial hypertension, pulmonary drug delivery, Pulmonary hypertension with interstitial lung disease, Treprostinil, Veterans Administration

Family History of Premature Atherosclerotic Cardiovascular Disease and Lipoprotein(a) Levels: A Multi Cohort Analysis

Razavi AC, Bhatia HS, Dardari ZA, Mehta A, Nasir K, Blankstein R, Isiadinso I, Quyyumi AA, Vaccarino V, Fialkow JA, Khoury MJ, Coronado F, Budoff[...]

Recombinant Human Pro-Urokinase vs. Alteplase Within 4.5 hours of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Hashmi TM, Shafiq A, Zia R, Ashraf H, Burhan M, Ahmed M, Mesmar A, Ahmed R, Fonarow GC. Recombinant Human Pro-Urokinase vs. Alteplase Within 4.5[...]

Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous Electrocardiographic Monitoring Follow-Up: ADVANTAGE AF Phase 2

Reddy VY, Gerstenfeld EP, Schmidt B, Andrade JG, Nair D, Natale A, Saliba W, Sommer P, Metzner A, Verma A, Hounshell T, Amin A, Gentlesk[...]